Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).

@article{LeirisaloRepo2013InfliximabF6,
  title={Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study).},
  author={Marjatta Leirisalo-Repo and Hannu Kautiainen and Leena Laasonen and M. Korpela and Markku J. Kauppi and Oili A Kaipiainen-Sepp{\"a}nen and Riitta Luosuj{\"a}rvi and Reijo K Luukkainen and Anna H Karjalainen and Harri Bl{\aa}field and Toini I Uutela and Kirsti Ilva and Heikki A Julkunen and Leena H Paimela and Kari T Puolakka and Eeva Moilanen and Pekka J Hannonen and Timo M{\"o}tt{\"o}nen},
  journal={Annals of the rheumatic diseases},
  year={2013},
  volume={72 6},
  pages={851-7}
}
OBJECTIVE Early treatment of patients with rheumatoid arthritis (RA) with combination treatment starting with methotrexate, sulfasalazine, hydroxychloroquine and prednisolone (FIN-RACo strategy) is superior to monotherapy. A study was undertaken to determine whether infliximab (INFL) added to intensified FIN-RACo treatment for the initial 6 months improves the 2-year outcome. METHODS 99 patients with early untreated active RA were enrolled in an investigator-initiated, randomised, double… CONTINUE READING